tbuckley/cabot-search huggingface dataset:
Effect of delaying therapy in newly diagnosed AML
Authors: e. estey, P. Thall, X. Wang, G. Borthakur, F. Ravandi-Kashani
Journal: Journal of Clinical Oncology (2007)

7020 Background: Given CR rates &lt; 50% in pts with chromosome 5 and/or 7 abnnormalities given standard therapies, such pts might be offered investigational treatments at diagnosis. However the delay entailed in waiting for cytogenetic results might be problematic. Here we examine the effect on survival time and CR rate of the interval (TDT) from M.D. Anderson (MDA) diagnosis to start of treatment. Methods: At physicians’ discretion, therapy was delayed (TDT &gt; 0) in 97% of the 1,378 pts with WBC &lt; 50,000 treated at MDA 1996-2005. We used regression models to evaluate TDT's effect on survival and CR, after accounting for other covariates measured on day 1 of treatment. Covariates strongly associated with TDT were represented as binary variables (Z) and evaluated using interactive terms of the type Z*TDT. Results: TDT was = 2 days in 24% of pts, = 1 week in 68%, and = 10 days in 80%. TDT was longer in older pts, those with performance status (PS) 0–2, no fever or infection, a higher albumin, and lower WBC count and % marrow blasts (p &lt; .02 for each). Considered alone, TDT had no effect on survival time (p= .33). However, longer TDT was independently associated with shorter survival in pts age &gt; 62, with fever or infection, PS 3–4, (p &lt; .001 for each), WBC &gt; 5.0 and marrow blasts &gt; 43% (p NS for each). A longer TDT was independently beneficial only for patients with an albumin &gt; 3.4 (p= 0.007) with the values for the numerical covariates being the medians for the 1,368 patients. The albumin at MDA diagnosis remained unchanged relative to the median at time of treatment in 60% of the 103 pts in whom TDT = 7 days; corresponding value for WBC was 88%, with the presence (absence) of fever or infection unchanged in 85%. Adding the effect of the above noted covariates, delaying treatment within the range of TDTs seen here did not decrease survival in 86% of our 703 pts &lt; age 63; exceptions were pts with PS &gt; 2 or with fever/ infection. However longer TDT shortened survival in 57% of the 675 pts age &gt; 62; exceptions were pts with PS &lt; 3, albumin &gt; 3.4, and no fever/infection. The effect of TDT on CR rate mirrored its effect on survival. Conclusions: Recalling the passage of time between outside diagnosis and referral to MDA, our results suggest that delaying start of treatment to ascertain cytogenetic (and in the future molecular) results is feasible in most younger, but probably not in most older, pts. No significant financial relationships to disclose.
Extrahepatic cholangiocarcinoma in a patient with situs inversus totalis diagnosed by endoscopic ultrasound
Authors: T. Togliani, S. Pilati, N. Mantovani, A. Savioli, L. Gaetti, S. Negri, P. Fusaroli
Journal: Endoscopy (2013)

Situs inversus totalis (SIT) is a rare congenital abnormality characterized by a left–right reversal of the positions of the internal organs. A 67-year-old man with SIT came to our attention with a recent onset of jaundice.
492 HOST GENETIC VARIANTS AROUND IL28A/IL28B ASSOCIATED WITH HCV-RELATED OUTCOMES BASED ON R.E.V.E.A.L.-HCV COHORT
Authors: G.T.W. Shaw, M.-H. Lee, Y. Yuan, H.-I. Yang, Y.-J. Lin, C.-L. Jen, S.-N. Lu, L.-Y. Wang, S.-L. You, G. L'Italien, C.-J. Chen
Journal: Journal of Hepatology (2013)
SAT0349 A Tailored Approach to Reduce Dose of Anti-TNF Drugs is Equally Effective, but Substantially Less Costly than Standard Dosing in Patients with Ankylosing Spondylitis over One Year: A Matched Observational Study: Table 1
Authors: J. Zavada, M. Uher, K. Sisol, S. Forejtova, K. Jarosova, H. Mann, J. Vencovsky, K. Pavelka
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> To compare efficacy, safety and costs of standard versus individually tailored reduced doses of anti-TNF drugs in patients with ankylosing spondylitis (AS) after achieving low disease activity over one year <h3>Methods</h3> One year outcome was compared between two prospectively followed cohorts of AS patients treated in a single academic centre with either reduced doses (n=53), or standard doses (n=83) of anti-TNF drugs. Both treatment groups were matched for patients9 age, gender, baseline activity, baseline function, duration of anti-TNF therapy and number of previous anti-TNF drugs. The change in measures of disease activity, physical function, and quality of life, as well as number of relapses, adverse events and costs of anti-TNF drugs were compared between both groups. The study covered the time period between 2007 and 2013 <h3>Results</h3> In the reduced dosing group at baseline (after initial dose reduction) the median dose was 67% of standard dose, and 50% at 12 months; in 21% patients the dose was further decreased during one year of observation, while the same proportion of patients required a return to standard dosing regimen. All measures of activity and function, as well as their mean change, were comparable between both treatment groups at baseline and at 12 months of observation. The incidence of relapses, adverse events, severe adverse events, infections, infusion reactions and switches between anti-TNF drugs did not differ between both treatment groups. While the quality of life did not differ between both groups, the annual costs of anti-TNF therapy were substantially lower (by about one third) in the group with reduced dosing. <h3>Conclusions</h3> A tailored approach to reduce doses of anti-TNF drugs in patients with AS after reaching low disease activity was a cost-effective strategy over one year of treatment. <h3>Acknowledgements</h3> This work was supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00023728. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3351
NEUTROPHIL TO PLATELET RATIO: A NOVEL PROGNOSTIC BIOMARKER IN STEMI PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION
Authors: Gaetano M. De Ferrari, Alberto Somaschini, Stefano Cornara, Antonella Pepe, Claudia Pavesi, Rita Camporotondo, Alessandra Repetto, Antonella Potenza, Massimiliano Gnecchi, Maurizio Ferrario
Journal: Journal of the American College of Cardiology (2015)
Ten years after Dublin: principal trends in HIV surveillance in the EU/EEA, 2004 to 2013
Authors: A Pharris, G Spiteri, T Noori, A J Amato-Gauci
Journal: Eurosurveillance (2014)

In 2004, the 31 countries of the European Union and European Economic Area (EU/EEA) adopted the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia. In 2013, 29,157 persons were diagnosed with HIV in 30 EU/EEA countries (adjusted rate: 6.2/100,000); new diagnoses have increased by 33% since 2004 among men who have sex with men and late diagnosis remains common. Evidence-based prevention measures and efforts towards earlier testing need to be expanded.
National Association for Patient Participation (NAPP) replies to article on patient participation groups in general practice
Authors: Patricia Wilkie, Paul Devlin
Journal: BMJ (2016)

The National Association for Patient Participation (NAPP; http://www.napp.org.uk) welcomes Gillam and Newbould’s article because the GP contract requires that all practices have a patient participation group (PPG) by April 2016.1 The statements that “millions of pounds have been spent on PPGs in the past five years” and “there remains uncertainty about …
Neurologist Comfort in the Use of Next-Generation Sequencing Diagnostics
Authors: Guy Helman, Joshua L. Bonkowsky, Adeline Vanderver
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Imaging Pediatric Plasmacytoid Dendritic Cell Neoplasm With FDG PET/CT
Authors: Patrick Martineau, Matthieu Pelletier-Galarneau, Sophie Turpin, Raymond Lambert
Journal: Clinical Nuclear Medicine (2016)

Blastic plasmacytoid dendritic cell neoplasm is a rare malignancy characterized by cutaneous involvement and hematological dissemination. Most affected patients are older, usually in the sixth or seventh decade of life, and this condition has rarely been described in the pediatric population. This report presents the case of a 9-year-old boy with blastic plasmacytoid dendritic cell neoplasm and demonstrates the utility of FDG PET/CT for staging and treatment follow-up.
A Comparison of the Diuretic Effects of Mercuhydrin (Meralluride) Administered by Several Routes
Authors: Raymond Marsh, Theodore Greiner, Harry Gold, Sydney Mathes, Frank Palumbo, Leon Warshaw, John Weaver
Journal: New England Journal of Medicine (1952)

THE relative efficacy of the mercurial diuretics by various modes of administration is a matter of considerable practical importance. On intravenous injection, these compounds sometimes produce serious reactions,1 , 2 and because the occasional fatal reaction is confined almost exclusively to this route of administration, there has been a tendency to turn to the intramuscular injection for routine treatment.3 The desirability of instructing patients in the technic of self-injection to avoid the need of a physician for each dose in the more intensive systems of treatment has focused attention on the subcutaneous injection as a technic that patients or members of the . . .
Abstract 4285: Hypoxia-mediated autophagy enhances HGF-induced cancer cell invasion.
Authors: Young H. Lee, Donald P. Bottaro
Journal: Cancer Research (2013)

Abstract The cellular response to hypoxia is a major influence on the aggressiveness of primary tumors, yet much of how this response mechanism influences other signaling pathways is unknown. The MET proto-oncogene, which encodes the tyrosine kinase receptor for hepatocyte growth factor (HGF), is often overexpressed in cancers and can drive cell proliferation, invasion, and metastasis. Prior studies demonstrate that the Met tyrosine-kinase receptor drives cell invasion and metastasis under hypoxic conditions, and this invasive phenotype is lost if MET expression is inhibited. Hypoxia also has been shown to sensitize Met-activated pathways to drive HGF-induced invasion through as yet undefined a molecular mechanism. The high mortality rate of metastatic cancer makes it crucial to understand the functional integration of these two prevalent drivers of metastasis, hypoxia and Met signaling, and to identify ways to selectively block cancer cell invasiveness. We show that a chemically generated pseudo-hypoxic condition enhanced HGF-mediated invasion in the papillary renal cell (PRC) carcinoma cell lines ACHN and UOK112. Under hypoxic conditions, cells generated high levels of ROS, which in turn sensitized the mitogen-activated protein kinase (MAPK) pathway to enhance HGF-driven invasion. Furthermore, hypoxic cells displayed increased autophagy as determined by punctate staining of LC3 II using immunocytochemistry and cleaved LC3 immunoblotting. Inhibition of autophagy decreased cell invasion and hypoxia-mediated autophagy was dependent on MAPK pathway activation. These data suggest that hypoxia promotes the invasiveness of PRC-derived cells by increasing ROS-mediated autophagy to sensitize the MAPK pathway to HGF stimulation. Identifying the specific effectors responsible for the integration these signals will improve our understanding of pro-metastatic invasiveness and potentially identify novels targets for its selective blockade. Citation Format: Young H. Lee, Donald P. Bottaro. Hypoxia-mediated autophagy enhances HGF-induced cancer cell invasion. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4285. doi:10.1158/1538-7445.AM2013-4285
O4.08 * AGI5198, AN INHIBITOR OF IDH1R132H, PROTECTS IDH1R132H HCT116 CELLS AGAINST IRRADIATION
Authors: R. J. Molenaar, D. Dimitrakopoulou, J. Stap, F. E. Bleeker, C. J. F. Van Noorden
Journal: Neuro-Oncology (2014)

BACKGROUND: IDH1R132H mutations are both inaugural events in the formation of glioma and associated with prolonged glioma patient survival. The IDH1R132H mutation confers a neo-enzymatic function that results in accumulation of the oncometabolite D-2-hydroxyglutarate (D-2HG), which promotes gliomagenesis by inducing global DNA hypermethylation and HIF1a degradation. AGI5198 is an IDH1R132H inhibitor that reduces proliferation of IDH1R132H tumors and will soon be tested in clinical trials with patients with IDH1R132H glioma. METHODS: An IDH1R132H mutation was generated in HCT116 cells by AAV targeting technology GENESIS (Horizon Discovery Ltd). Both IDH1WT/WT and IDH1R132H/WT mutant HCT116 cells were irradiated with 0-6 Gy γ-rays (IR) and/or incubated with 5 µM reactive oxygen species-scavenger N-acetyl cysteine (NAC) and/or 0-400 nM IDH1R132H inhibitor AGI5198. The effects were tested in clonogenic assays. Clones were chemically fixed and stained 10 days after IR. RESULTS: As compared with IDH1WT/WT HCT116 cells, we observed a reduced surviving fraction of IDH1R132H/WT HCT116 cells at all IR dosages. This suggests that IDH1R132H/WT HCT116 cells demonstrated increased sensitivity for IR. We pre-incubated both HCT116 cell lines with AGI5198 before IR. With increasing concentrations of AGI5198, we observed higher surviving fractions of IDH1R132H/WT HCT116 cells. There was no difference between the surviving fractions of AGI5198-treated and untreated IDH1WT/WT HCT116 cells. This indicates that AGI5198 protects IDH1R132H/WT HCT116 cells against IR in a dose-dependent fashion, but had no protecting effect against IR on IDH1WT/WT HCT116 cells. Next, we treated both HCT116 cell lines with NAC before IR. NAC equalized the surviving fractions of IDH1WT/WT and IDH1R132H/WT HCT116 cells after IR. This suggests that oxidative stress is an important component of the increased sensitivity of IDH1R132H/WT HCT116 cells for IR. CONCLUSION: Our results show that prolonged survival of IDH1R132H glioma patients, as compared to IDH1WT glioma patients, may be at least partly explained by an increased sensitivity of IDH1R132H cells to IR. In addition, our data suggest that AGI5198 reverses IR sensitivity of IDH1R132H/WT HCT116 cells. Since AGI5198 and IR counteract in our cell model, concomitant administration of IDH1R132H inhibitors and IR may be contraindicated because IDH1R132H inhibitors may decrease tumor response to IR.
THU0326 Association between Anti-C1 Q and Other Markers of Disease Activity with Nephritis in a Population of 160 Portuguese Patients with Systemic Lupus Erythematosus
Authors: G. Terroso, M. Bernardes, A. M. Pereira, A. Bodas, A. Aleixo, P. Madureira, R. Vieira, R. Fonseca, D. Gonçalves, L. Costa
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Anti-C1q autoantibodies have been described in patients with systemic lupus erythematosus (SLE) and their presence has been closely correlated with renal disease activity. Serum anti-C1q determination seems to be a valuable non-invasive marker for prediction of renal histopathology in lupus nephritis. <h3>Objectives</h3> To assess if anti-C1q and other markers of disease activity are associated with nephritis according to renal BILAG score in a population of patients with SLE. <h3>Methods</h3> A sample of portuguese SLE patients was grouped according to BILAG renal score: categories A+ B+ C (active nephritis), category D (inactive nephritis) and category E (no nephritis). Anti-C1q autoantibodies were determined by ELISA (Bühlmann®) with duplicate samples. Levels &lt; 15 units/mL were considered the cut-off for normal sera. Serum ESR, CRP, levels of C3c, C4, CH50, anti-DNAds titres, 25(OH)vitamin D, 24 hour protein excretion and SLEDAI were measured. A multivariate analysis was performed using SPSS 18.0. Adjustments were made for patients´age, disease duration, steroid daily dose (prednisolone equivalents) and hydroxychloroquine daily dose. <h3>Results</h3> 160 patients, 148 (92.5%) women, with mean (SD) age of 44.2± 12.59 years, were grouped according to BILAG renal score in categories A+B+C (n=23; 14.4%), category D (n=45; 28.1%) and category E (n=92; 57.5%). All the patients with a history of nephritis (active or previous) had had a biopsy at the time of its diagnosis (n=68; 42.5%). They had mean (SD) disease duration of 12.2± 8.71 years, SLEDAI 3.1± 4.50, SLICC 0.6± 1.07, daily dose of prednisolone 6.5 ± 5.91 mg and of hydroxychloroquine 213.2± 192.76 mg. An association was found between active renal disease (BILAG score categories A+ B+ C) and higher anti-C1q titres (p&lt;0.01), higher anti-dsDNA titres (p&lt;0.01) and lower C3c levels (p&lt;0.01). <h3>Conclusions</h3> In a cohort of portuguese SLE patients, an association was found between anti-C1q titres, C3c levels and anti-dsDNA titres with active nephritis evaluated by BILAG renal scores. These data support the use of anti-C1q as a marker of nephritis presence and activity in SLE. <h3>References</h3> Yang XW, Tan Y, Yu F, Zhao MH, Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrol Dial Transplant. 2012 Sep(9):3552-9. Doi:10.1093/ndt/gfs179. Chen Z, Wang GS, Wang GH, Li XP, Anti-C1q antibody is a valuable biological marker for prediction of renal pathological characteristics in lupus nephritis. Clin Rheumatol. 2012 Sep;31(9):1323-9. doi: 10.1007/s10067-012-2017-1. <h3>Disclosure of Interest</h3> None Declared
Evaluation of the Health Protection Event-Based Surveillance for the London 2012 Olympic and Paralympic Games
Authors: E Severi, A Kitching, P D Crook
Journal: Eurosurveillance (2014)

The Health Protection Agency (HPA) (currently Public Health England) implemented the Health Protection Event-Based Surveillance (EBS) to provide additional national epidemic intelligence for the 2012 London Olympic and Paralympic Games (the Games). We describe EBS and evaluate the system attributes. EBS aimed at identifying, assessing and reporting to the HPA Olympic Coordination Centre (OCC) possible national infectious disease threats that may significantly impact the Games. EBS reported events in England from 2 July to 12 September 2012. EBS sourced events from reports from local health protection units and from screening an electronic application 'HPZone Dashboard' (DB). During this period, 147 new events were reported to EBS, mostly food-borne and vaccine-preventable diseases: 79 from regional units, 144 from DB (76 from both). EBS reported 61 events to the OCC: 21 of these were reported onwards. EBS sensitivity was 95.2%; positive predictive value was 32.8%; reports were timely (median one day; 10th percentile: 0 days - same day; 90th percentile: 3.6 days); completeness was 99.7%; stability was 100%; EBS simplicity was assessed as good; the daily time per regional or national unit dedicated to EBS was approximately 4 hours (weekdays) and 3 hours (weekends). OCC directors judged EBS as efficient, fast and responsive. EBS provided reliable, reassuring, timely, simple and stable national epidemic intelligence for the Games.
AB0663 Discontinuation of Anti-TNF-Alpha Therapy in Patients with Ankylosing Spondylitis
Authors: H.G. Vasiljeva, A.V. Elonakov, R.V. Gorenkov
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The effectiveness of anti-tumor necrosis factor -alpha therapy (anti-TNF-α) is well known, but the discontinuation of this therapy is insufficiently studied. <h3>Objectives</h3> To analyze consequences and safety of anti-TNF-α therapy after discontinuation in patients with ankylosing spondylitis (AS). <h3>Methods</h3> 79 patients with AS were included in the research: 72 with axial AS and 7 with peripheral AS. All these patients discontinued anti-TNF-α therapy from 1 week to 54 weeks. The age of patients was from 18 years to 75 years. There were 74% men and 26% women. The remission was from 2 weeks to 6,5 years. The duration of current biological therapy was from 14 weeks to 9 years. The duration of disease was from 3 years to 46 years. 37 patients (86%) were HLA B27-positive and 6 patients (14%) HLA B27-negative among those who had done this test. The following criteria were used for assessment of disease activity in the result of anti-TNF-α therapy discontinuation: BASFI, BASDAI, DFI, VAS, CRP, ESR. Clinical relapse was defined as: BASDAI≥4, BASFI≥4, DFI≥4, VAS≥6, increase in CRP and ESR. <h3>Results</h3> The vast majority of patients who discontinued the anti-TNF-α therapy had clinical relapse. The mean time of relapse after the discontinuation of biological therapy was 14,1±12,2 weeks (p&lt;0.05) for patients with axial AS and 8,5±4,6 weeks (p&lt;0.05) for patients with peripheral AS. Relapse developed slower among patients who had a long remission. Patients with frequent discontinuations (4 and 5 times) were accompanied by faster developing of relapse in every subsequent break. There was only one patient with axial AS who continued to be in remission after long discontinuation (54 weeks). He was HLA B27 – positive, the duration of disease was 20 years, the duration of biological therapy by etanercept was 2,75 years. There is the correlation between the duration of biological therapy9s discontinuation and developing of relapse. Longer the break is, worse indexes BASDAI, BASFI, DFI, VAS, ESR and CRP indicators are. 83% patients who had uveitis after discontinuation of biological therapy had relapse in uveitis, 17% patients hadn9t. <h3>Conclusions</h3> The interruption of anti-TNF-α therapy in patients with ankylosing spondylitis is unsafe and in the majority of cases leads to clinical relapse. AS-therapy must be permanent and uninterrupted. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4438